Dr Fisher is a Senior Clinical Lecturer in Rheumatology at the University of Birmingham and a Deputy Clinical Director of the Cancer Research UK Clinical Trials Unit, Birmingham. His principal research interests are Sjögren’s Syndrome and inflammatory arthritis, including checkpoint inhibitor-induced arthritis. He is clinical lead for the OASIS Sjögren’s cohort and Sjögren’s clinical trials at the Queen Elizabeth Hospital Birmingham. He was Co-CI for the CATALYST phase 2 platform trial investigating novel therapies for hospitalised patients with COVID-19 pneumonia.